In brief, this S1PR1/pSTAT3 risk category was useful for predicting the prognosis of DLBCL patients who were defined as follows: 1) high risk: S1PR1+, 2) intermediate risk: S1PR1-/pSTAT3+, and 3) low risk group: S1PR1-/pSTAT3-. This evidence concerns the gene S1PR1 and diffuse large B-cell lymphoma.